A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

We recently published a list of the 11 Best Undervalued UK Stocks to Buy Right Now. In this article, we are going to take a ...

GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of ...

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

The Advisory Committee on Immunization Practices (ACIP) has voted to expand the recommended use of GSK’s AREXVY (Respiratory ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

In 2023 – the first year that Arexvy and Abrysvo were approved – the ACIP's recommendation was that they could be used in all adults over the age of 60 if deemed appropriate by their doctor ...

Stocks ended in the red for the holiday-shortened week, as developments over tariffs and tensions between U.S. President Donald Trump and Federal Reserve chair Jerome Powell continued to dominate ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...